Optic IconOptic Logo
|
SearchCollectionsBenchmarks

9-ING-41

1 abstract

Abstract
Plasma cytokine profiles and survival outcomes in the 1801 phase 1/2 clinical trial of 9-ING-41 (elraglusib) in patients with advanced cancer.
Org: Legorreta Cancer Center, Winship Cancer Institute of Emory University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, DTC, Actuate Therapeutics, Inc.,